Abstract
The global shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, which are highly sought after as treatments for type 2 diabetes and obesity, is increasing. This deficit is attributed to the unexpected increase in demand for GLP-1 receptor agonists. This has caused significant harm to patients with type 2 diabetes mellitus who are already using GLP-1 receptor agonists for blood sugar management, weight loss, or reduction of cardiovascular risk or those who are looking to start. To address this situation, doctors need to adjust medications considering the patient condition and clinical guidelines and must provide better education on lifestyle modifications such as diet and exercise. Close cooperation between regulatory agencies and manufacturers is needed to mass-produce GLP-1 receptor agonists, as are societal efforts to prevent the trend of GLP-1 receptor agonist use as diet pills.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
